THE CHOLINERGIC APPROACH FOR THE TREATMENT OF VASCULAR DEMENTIA: EVIDENCE FROM PRE-CLINICAL AND CLINICAL STUDIES

REFERENCES

• Jorm A. F., Korten A. E., Henderson A. S. The Prevalence of Dementia: a Quantitative Integration of the Literature. Acta Psychiatr. Scand. 1987; 76: 465–479
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T. Cerebral Dementia. Pathophysiology, Diagnosis and Treatment. CNS Drugs 1999; 12: 35–48
   Web of Science ®Google Scholar
• Rockwood K., Wentzel C., Hachinski V., Hogan D. B., Macknight C., McDowell I. Prevalence and Outcome of Vascular Cognitive Impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54: 447–451
   PubMed Web of Science ®Google Scholar
• Sultzer L. D., Cummings J. L. Secondary Dementia in the Elderly. Clinical Neurology of Aging, M. L. Albert, J. E. Knoefel. Oxford University Press, New York 1994; 379–395
   Google Scholar
• Kurz F. A. What in Vascular Dementia?. Int. J. Clin. Pract. 2001; Suppl. 120: 5–8
   Google Scholar
• Roman G. C., Tatemichi T. K., Erkinjuntti T., Cummings J. L., Masdeu J. C., Garcia J. H., Amaducci L., Orgogozo J. M., Brun A., Hofman A. Vascular Dementia: Diagnostic Criteria for Research Studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–260., et al.
   PubMed Web of Science ®Google Scholar
• Gold G., Giannakopoulos P., Montes-Paixao Junior C., Herrmann F. R., Mulligan R., Michel J. P., Bouras C. Sensitivity and Specificity of Newly Proposed Clinical Criteria for Possible Vascular Dementia. Neurology 1997; 49: 690–694
   PubMed Web of Science ®Google Scholar
• Verhey F. R., Lodder J., Rozendaal N., Jolles J. Comparison of Seven Sets of Criteria Used for the Diagnosis of Vascular Dementia. Neuroepidemiology 1996; 15: 166–172
   PubMed Web of Science ®Google Scholar
• Hachinski V. C., Iliff L. D., Zilhka E., DuBoulay G. H., McAllister V. L., Marshall J., Russel R.W. R., Symon L. Cerebral Blood Flow in Dementia. Arch. Neurol. 1975; 32: 632–637
   PubMed Web of Science ®Google Scholar
• The America Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington DC 1994
   Google Scholar
• Moroney J. T., Bagiella E., Desmond D. W., Hachinski V. C., Molsa P. K., Gustafson L., Brun A., Fischer P., Erkinjuntti T., Rosen W., Paik M. C., Tatemichi T. K. Meta-Analysis of the Hachinski Ischemic Score in Pathologically Verified Dementias. Neurology 1997; 49: 1096–1105
   PubMed Web of Science ®Google Scholar
• Bowen D. M., Francis P. T., Chessel I. P., Webster M. T. Alzheimer's Disease: is the Improvement of Cholinergic Transmission the Correct Strategy?. Alzheimer's Disease: Clinical and Treatment Perspectives, C. G. Cutler, K. Goddfries, S. Kasper. John Wiley & Sons, ChichesterEngland 1995; 235–255
   Google Scholar
• Avery E. E., Baker L. D., Asthana S. Potential Role of Muscarinic Agonists in Alzheimer's Disease. Drugs Aging 1997; 11: 450–459
   PubMed Web of Science ®Google Scholar
• Muir J. L. Acetylcholine, Aging, and Alzheimer's Disease. Pharmacol. Biochem. Behav. 1997; 56: 687–696
   PubMed Web of Science ®Google Scholar
• Drachman D. A. Memory and Cognitive Function in Man: Does the Cholinergic System Have a Specific Role?. Neurology 1977; 40: 526–530
   Google Scholar
• Gottfries C. G. Neurochemical Aspects of Dementia Disorder. Dementia 1990; 1: 56–64
   Google Scholar
• Mc Entee W. J., Crook T. H. Age-Associated Memory Impairment: a Role of Catecholamines. Neurology 1990; 40: 526–530
   PubMed Web of Science ®Google Scholar
• Davies P., Maloney A.J. F. Selective Loss of Central Cholinergic Neurons in Alzheimer's Disease. Lancet 1976; ii: 1403
   Google Scholar
• Bowen D. M. Biochemistry of Dementias. Proc. R. Soc. Med. 1977; 70: 351–353
   PubMedGoogle Scholar
• Nordberg A. Neuroreceptor Changes in Alzheimer's Disease. Cerebrovasc. Brain Metab. Rev. 1992; 4: 303–328
   PubMedGoogle Scholar
• Hellstrom-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional Distribution of Nicotinic Receptor Subunit mRNAs in Human Brain: Comparison Between Alzheimer and Normal Brain. Brain Res. Mol. Brain Res. 1999; 66: 94–103
   PubMedGoogle Scholar
• Drachman D. A., Leavitt J. Human Memory and the Cholinergic System. A Relationship to Aging?. Arch. Neurol. 1974; 30: 113–121
   PubMed Web of Science ®Google Scholar
• Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle J. T., Delon M. R. Alzheimer's Disease and Senile Dementia: Loss of Cholinergic Neurones in the Basal Forebrain. Science 1982; 215: 1237–1239
   PubMed Web of Science ®Google Scholar
• Gray J. A., Enz A., Spiegel R. Muscarinic Agonist for Senile Dementia: Past Experience and Future Trends. Trends Pharmacol. Sci. 1989; 1: 85–88
   Google Scholar
• Bartus R. T., Dean III. R. L., Beer B., Lippa A. S. The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 1982; 217: 408–417
   PubMed Web of Science ®Google Scholar
• Kerr J. S., Sherwood N., Hindmarch I. Separate and Combined Effects of the Social Drugs on Psycomotor Performance. Psychopharmacology 1991; 104: 113–119
   PubMed Web of Science ®Google Scholar
• Rusted J. Effects of Post-trial Administration of Nicotin on Human Memory: Evaluating the Condition for Improving Memory. Psychopharmacology 1995; 119: 405–413
   PubMed Web of Science ®Google Scholar
• Sahakian B. J., Jones G.M. M. The Effects of Nicotin on Attention Information Process, and Working Memory in Patients with Dementia of Alzheimer Type. Effects on Nicotin on Biological Systems, F. Adlkofer, F. Thruau. Birkhauser Verlag, Basel 1991; 623–630
   Google Scholar
• Whitehouse P. J., Kalaria R. N. Nicotinic Receptors and Neurodegenerative Dementing Diseases: Basic Research and Clinical Implications. Alzheimer Dis. Assoc. Disord. 1995; 9: 3–5
   PubMed Web of Science ®Google Scholar
• Perry E. K., Morris C. M., Court J. A., Cheng A., Fairbairn A. F., McKeith I. G., Irving D., Brown A., Perry R. H. Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology. Neuroscience 1995; 64: 385–395
   PubMed Web of Science ®Google Scholar
• Gallagher M., Colombo P. J. Ageing: The Cholinergic Hypothesis of Cognitive Decline. Curr. Opin. Neurobiol. 1995; 5: 161–168
   PubMed Web of Science ®Google Scholar
• Kasa P., Rakonczay Z., Gulya K. The Cholinergic System in Alzheimer's Disease. Prog. Neurobiol. 1997; 52: 511–535
   PubMed Web of Science ®Google Scholar
• Maelicke A. Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer's Disease. Dement. Geriatr. Cogn. Disord. 2000; 11: 11–18
   PubMed Web of Science ®Google Scholar
• Saito H., Togashi H., Yoshioka M., Nakamura N., Minami M., Parvez H. Animal Models of Vascular Dementia with Emphasis on Stroke-Prone Spontaneously Hypertensive Rats. Clin. Exp. Pharmacol. Physiol. 1995; 222: S257–S259
   Google Scholar
• Togashi H., Matsumoto M., Yoshioka M., Hirokami M., Minami M., Saito H. Neurochemical Profiles in Cerebrospinal Fluid of Stroke-Prone Spontaneously Hypertensive Rats. Neurosci. Lett. 1994; 166: 117–120
   PubMed Web of Science ®Google Scholar
• Kimura S., Saito H., Minami M., Togashi H., Nakamura N., Nemoto M., Parvez H. S. Pathogenesis of Vascular Dementia in Stroke-Prone Spontaneously Hypertensive Rats. Toxicology 2000; 153: 167–178
   PubMed Web of Science ®Google Scholar
• Togashi H., Kimura S., Matsumoto M., Yoshioka M., Minami M., Saito H. Cholinergic Changes in the Hippocampus of Stroke-Prone Spontaneously Hypertensive Rats. Stroke 1996; 27: 520–526
   PubMed Web of Science ®Google Scholar
• Ferrari R., Frasoldati A., Leo G., Torri C., Zini I., Agnati L. F., Zoli M. Changes in Nicotinic Acetylcholine Receptor Subunit mRNAs and Nicotinic Binding in Spontaneously Hypertensive Stroke Prone Rats. Neurosci. Lett. 1999; 277: 169–172
   PubMed Web of Science ®Google Scholar
• Tajima A., Hans F. J., Livingstone D., Wei L., Finnegan W., DeMaro J., Fenstermacher J. Smaller Local Brain Volumes and Cerebral Atrophy in Spontaneously Hypertensive Rats. Hypertension 1993; 21: 105–111
   PubMed Web of Science ®Google Scholar
• Amenta F., Strocchi P., Sabbatini M. Vascular and Neuronal Hypertensive Brain Damage: Protective Effect of Treatment with Nicardipine. J. Hypertens. 1996; 14((Suppl. 3))S29–S35
   Google Scholar
• Nicotera P., Bellomo G., Orrenius S. Calcium-Mediated Mechanism in Chemically Induced Cell Death. Annu. Rev. Pharmacol. Toxicol. 1992; 32: 449–470
   PubMed Web of Science ®Google Scholar
• Sabbatini M., Strocchi P., Vitaioli L., Amenta F. The Hippocampus in Spontaneously Hypertensive Rats: a Quantitative Microanatomical Study. Neuroscienze 2000; 100: 251–258
   PubMed Web of Science ®Google Scholar
• Sabbatini M., Strocchi P., Vitaioli L., Amenta F. Microanatomical Changes of Intracerebral Arteries in Spontaneously Hypertensive Rats: a Model of Cerebrovascular Disease of the Elderly. Mech. Ageing Dev. 2001; 122: 1257–1268
   PubMed Web of Science ®Google Scholar
• Knardahl S., Karlsel K. Passive-Avoidance Behaviour of Spontaneously Hypertensive Rats. Behav. Neurol. Biol. 1984; 42: 9–22
   PubMedGoogle Scholar
• Sutturer J. R., Devito W. J., Rykaszewsky I. Developmental Aspect of 2-Way Shuttlebox Avoidance in Spontaneously Hypertensive and Normotensive Rat. Devl. Psychobiol. 1981; 14: 405–414
   PubMed Web of Science ®Google Scholar
• Sutturer J. R., Perry J., Devito W. J. Two-Way Shuttlebox and Lever-Press Avoidance in Spontaneously Hypertensive and Normotensive Rat. J. Comp. Physiol. Psychol. 1980; 94: 155–163
   PubMed Web of Science ®Google Scholar
• Meneses A., Castillo C., Ibarra M., Hong E. Effects of Aging and Hypertension on Learning, Memory and Activity in Rats. Physiol. Behav. 1996; 60: 341–345
   PubMed Web of Science ®Google Scholar
• Wyss J. M., Fisk G., van Groen T. Impaired Learnig and Memory in Mature Spontaneously Hypertensive Rats. Brain Res. 1992; 592: 135–140
   PubMed Web of Science ®Google Scholar
• Mori S., Kato M., Fujishima M. Impaired Maze Learning and Cerebral Glucose Utilization in Aged Hypertensive Rats. Hypertension 1995; 25: 545–553
   PubMed Web of Science ®Google Scholar
• Nakamura-Palacios E. M., Caldas C. K., Fiorini A., Chagas K. D., Chagas K. N., Vasquez E. C. Deficits of Spatial Learning and Working Memory in Spontaneously Hypertensive Rats. Behav. Brain Res. 1996; 74: 217–221
   PubMed Web of Science ®Google Scholar
• Gattu M., Pauly J. R., Boss K. L., Summers J. B., Buccafusco J. J. Cognitive Impairment in Spontaneously Hypertensive Rats: Role of Central Nicotinic Receptors. Part I. Brain Res. 1997a; 771: 89–103
   PubMed Web of Science ®Google Scholar
• Gattu M., Terry A. V., Pauly J. R., Buccafusco J. J. Cognitive Impairment in Spontaneously Hypertensive Rats: Role of Central Nicotinic Receptors. Part II. Brain Res. 1997b; 771: 104–114
   PubMed Web of Science ®Google Scholar
• Terry A. V., Jr., Hernandez C. M., Buccafusco J. J., Gattu M. Deficits in Spatial Learning and Nicotinic-Acetylcholine Receptors in Older, Spontaneously Hypertensive Rats. Neurosci. 2000; 101: 357–368
   PubMed Web of Science ®Google Scholar
• Goffries C. G., Blennow K., Karlsson I., Wallin A. The Neurochemistry of Vascular Dementia. Dementia 1994; 393: 165–170
   Google Scholar
• Wallin A., Blennow K., Goffries C. G. Neurochemical Abnormalities in Vascular Dementia. Dementia 1989; 1: 120–130
   Google Scholar
• Tohgi H., Abe T., Kimura M., Saheki M., Takahashi S. Cerebrospinal Fluid Acetylcholine and Choline in Vascular Dementia of Binswanger and Multiple Small Infarct Types as Compared with Alzheimer-Type Dementia. J. Neural. Transm. 1996; 103: 1211–1220
   PubMed Web of Science ®Google Scholar
• Giacobini E. From Molecular Structure to Alzheimer's Therapy. Jpn. J. Pharmacol. 1997; 74: 225–241
   PubMedGoogle Scholar
• Giacobini E. Cholinesterase Inhibitors for Alzheimer's Disease: from Tacrine to Future Applications. Neurochem. Int. 1998; 32: 413–419
   PubMed Web of Science ®Google Scholar
• Rogers S. L., Mohs R., Dody R. S. ARICEPT International Project Team. Aricept: a Well-Tolerated and Clinically Effective Treatment for the Symptoms of AD. Results from World-Wide Clinical Trials. Alzheimer's Report 1 1998, Suppl. 1; S13–S14
   Google Scholar
• Birks J. S., Melzer D. Donepezil for Mild and Moderate Alzheimer's Disease. Cochrane Database Syst. Rev. 2 2000; CD001190
   Google Scholar
• Sisak E. Donepezil Treatment in Vascular Dementia. Second International Congress of Vascular Dementia. Abstract Book. 2002; 35
   Google Scholar
• Birks J., Iakovidou V., Tsolaki M. Rivastigmine for Alzheimer's Disease. Cochrane Database Syst. Rev. 2 2000; CD001191
   Google Scholar
• Moretti R., Torre P., Antonello R. M., Cazzato G., Bava A. Rivastigmine is Safe and Effective for at Least 22 Months in Patients with Subcortical Vascular Dementia. Second International Congress of Vascular Dementia. Abstract Book. 2002; 52
   Google Scholar
• Sweeney J. E., Bachaman E. S., Coyle J. T. Effects of Different Doses of Galantamine, a Long-Acting Acetylcholinesterase Inhibitor, on Memory in Mice. Psycopharmacology Berl. 1990; 102: 191–200
   PubMed Web of Science ®Google Scholar
• Chopin P., Briley M. Effects of Four Non-cholinergic Cognitive Enhancers in Comparison with Tacrine and Galantamine on Scopolamine-Induced Amnesia in Rats. Psycopharmacology 1992; 106: 26–30
   PubMed Web of Science ®Google Scholar
• Bores G. M., Huger F. P., Petko W., Mutlib A. E., Camacho F., Rush D. K., Selk D. E., Wolf V., Kosley R. W., Jr., Davis L., Vargas H. M. Pharmacological Evaluation of Novel Alzheimer's Disease Therapeutics: Acetylcholinesterase Inhibitors Related to Galanthamine. J. Pharmacol. Exp. Ther. 1996; 277: 728–738
   PubMed Web of Science ®Google Scholar
• Neufeld M. Y., Folgeson N., Kogan E., Korczyn A. D. The Effect of Galantamine on the Quantitative EEG in Vascular or Mixed Dementia. Second International Congress of Vascular Dementia. Abstract Book 2002; 40
   Google Scholar
• Geerts H., Grantham C. Should we be Studying Cholinergic Drugs for the Treatment of Vascular Dementia? Second International Congress of Vascular Dementia. Abstract Book 2002; 37
   Google Scholar
• Erkinjuntti T., Lilienfeld S. Galantamine Provides Broad Therapeutic Benefits in Patients with Probable Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease. Second International Congress of Vascular Dementia. Abstract Book 2002; 11
   Google Scholar
• Schwartz J. H. Chemical Messengers: Small Molecules and Peptides. Principles of Neural Science, E. R. Kandel, J. H. Schwartz, T. M. Jessel. Elsevier, New York 1991; 213–224, 3rd Ed.
   Google Scholar
• Thal L. J., Rosen W., Sharpless N. S., Crustal H. Choline Chloride Fails to Improve Cognition of Alzheimer's Disease. Neurobiol. Aging 1981; 2: 205–208
   PubMed Web of Science ®Google Scholar
• Brinkman S. D., Smith R. C., Meyer J. S., Vroulis G., Shaw T., Gordon J. R., Allen R. H. Lecithin and Memory Training in Suspected Alzheimer's Disease. J. Gerontol. 1982; 37: 4–9
   PubMedGoogle Scholar
• Davis R. E., Emmerling M. R., Jaen J. C., Moos W. H., Spiegel K. Therapeutic Intervention in Dementia. Crit. Rev. Neurobiol. 1993; 7: 41–83
   PubMed Web of Science ®Google Scholar
• Sakas D. E., Crowell R. M., Zervas N. T. Effects of Lecithin-Emulsified Perfluorochemical Compounds in Ischemic Brain Injury. Artif. Cell. Blood Sibstit. Immobil. Biotechnol. 1994; 22: 83–89
   PubMed Web of Science ®Google Scholar
• Suzuki S., Furushiro M., Takahashi M., Sakai M., Kudo S. Oral Administration of Soybean Lecithin Transphosphatidylated Phosphatidylserine (SB-Tps) Reduces Ischemic Damage in the Gerbil Hippocampus. Jpn. J. Pharmacol. 1999; 8: 237–239
   Google Scholar
• Higgins J.P. T., Flitcker L. Lecithin for Dementia and Cognitive Impairment. Cochrane Review, Database Syst. Rev. (2) 2000; CD001015
   Google Scholar
• Wecker L. Dietary Choline: a Limiting Factor for the Synthesis of Acetylcholine by the Brain. Advances in Neurology, R. J. Wurtman, J. K. Blussztajn, I. H. Ulus. Raven Press Ltd, New York 1990; 139–145
   Google Scholar
• Sigala S., Imperato A., Rizzonelli P., Casolini P., Missale C., Spano P. L-Alpha-Glycerylphosphorylcholine Antagonizes Scopolamine-Induced Amnesia and Enhances Hippocampal Cholinergic Transmission in the Rat. Eur. J. Pharmacol. 1992; 21: 351–358
   Google Scholar
• Rao A. M., Hatcher J. F., Dempsey R. J. Lipid Alterations in Transient Ischemia: Possible New Mechanisms of CDP-Choline Neuroprotection. J. Neurochem. 2000; 75: 2528–2535
   PubMed Web of Science ®Google Scholar
• Shuaib A., Yang Y., Li Q. Evaluating the Efficacy of Citicoline in Embolic Ischemic Stroke in Rats: Neuroprotective Effects When Used or in Combination with Urokinase. Exp. Neurol. 2000; 161: 733–739
   PubMed Web of Science ®Google Scholar
• Alvarez X. A., Sampaedro C., Lozano R., Cacabelos R. Citicoline Protects Hippocampal Neurons Against Apoptosis Induced by Brain Beta-Amyloid Deposits Plus Cerebral Hypoperfusion in Rats. Methods Find. Exp. Clin. Pharmacol. 1999; 21: 535–540
   PubMed Web of Science ®Google Scholar
• Fresta M., Werhli E., Puglisi G. Enhanced Therapeutic Effect of Cytidine-5′-Diphosphate Choline When Associated with GM1 Containing Small Liposomes as Demostrated in a Rat Ischemia Model. Pharm. Res. 1995; 12: 1769–1774
   PubMed Web of Science ®Google Scholar
• Centrone G., Ragno G., Calicchio G. Use of Citicoline in High Dosages in Acute Cerebrovascular Disease. Minerva Med. 1986; 77: 371–373
   PubMedGoogle Scholar
• Sinforiani E., Trucco M., Pacchetti C., Gualtieri S. Evaluation of the Effects of Citicoline in Chronic Cerebrovascular Diseases. Minerva Med. 1986; 77: 51–57
   PubMedGoogle Scholar
• Serra F., Diaspri G. P., Gasbarrini A., Giancane S., Rimondi A., Tame M. R., Sakellaridis E., Bernardi M., Gasbarrini G. Effect of CDP-Choline on Senile Mental Deterioration. Multicenter Experience on 237 Cases. Minerva Med. 1990; 81: 465–470
   PubMedGoogle Scholar
• Di Perri R., Coppola G., Ambrosio L. A., Grasso A., Puca F. M., Rizzo M. A Multicentre Trial to Evaluate the Efficacy and Tolerability of Alpha-Glycerylphosphorylcholine Versus Cytosine Diphosphocholine in Patients with Vascular Dementia. J. Int. Med. Res. 1991; 119: 330–341
   Google Scholar
• Clark W. M., Williams B. J., Selzer K. A., Zweifler R. M., Sabounjian L. A., Gammans R. E. A Randomized Efficacy Trial of Citicoline in Patients with Acute Ischemic Stroke. Stroke 1999; 30: 2592–2597
   PubMed Web of Science ®Google Scholar
• Clark W. M., Warach S. J., Pettigrew L. C., Gammans R. E., Sabounjian L. A. A Randomized Dose-Response Trial of Citicoline in Acute Ischemic Stroke Patients. Citicoline Stroke Study Group. Neurology 1997; 49: 671–678
   PubMed Web of Science ®Google Scholar
• Warach S., Pettigrew L. C., Dashe J. F., Pullicino P., Lefkowitz D. M., Sabounjian L. A., Harnet K., Schwiderski U., Gammans R. Effect of Citicoline on Ischemic Lesions as Measured by Diffusion-Weighted Magnetic Resonance Imaging. Citicoline 010 Investigators. Ann. Neurol. 2000; 48: 713–722
   PubMed Web of Science ®Google Scholar
• Fioravanti M., Yanagi M. Cytidinephosphocholine (CDP choline) for Cognitive and Behavioural Disturbances Associated with Chronic Cerebral Disorders in the Elderly. Cochrane Databese Syst. Rev. 2000; CD000269
   Google Scholar
• Govoni S., Lopez C., Battaini F., Longoni A., Trabucchi M. Effetti di αGFC sul Comportamento di Evitamento Passivo del Ratto e sui Livelli di Acetilcolina. Basi Raz. Ter. 1990; 20: 55–60
   Google Scholar
• Schettini G., Florio T., Ventra C., Grimaldi M., Meucci O., Landolfi E. Effetto del Trattamento In Vivo con αGFC (colina alfoscerato) sull'attività dei Sistemi di Trasduzione a Livello Cerebrale. Basi Raz. Ter. 1990; 20: 23–30
   Google Scholar
• Amenta F., Franch F., Ricci A., Vega J. A. Cholinergic Neurotrasmission in the Hippocampus of Aged Rats: Influence of L-Alpha-Glycerylphosphorylcholine Treatment. Ann. N.Y. Acad. Sci. 1993; 695: 311–313
   PubMed Web of Science ®Google Scholar
• Aleppo G., Nicoletti F., Sortino M. A., Casabona G., Scapagnini U., Canonico P. L. Chronic L-Alpha-Glycerylphosphorylcholine Increase Inositol Phosphate Formation in Brain Slices and Neuronal Cultures. Pharmacol. Toxicol. 1994; 74: 95–100
   PubMedGoogle Scholar
• Canonico P. L., Nicoletti F., Scapagnini U. Effetti Neurochimici e Comportamentali di αGFC (Colina Alfoscerato). Basi Raz. Ter. 1990; 20: 53–54
   Google Scholar
• Drago F., Nardo L., Freni V., Spadaro F., Valerio C. Effetti Comportamentali di αGFC in Modelli di Invecchiamento Cerebrale Patologico. Basi Raz. Ter. 1990; 20: 65–68
   Google Scholar
• Frattola L., Piolti R., Bassi S., Albizzati M. G., Galletti G., Grumelli B. Colina Alfoscerato (αGFC) nel Trattamento della Demenza Multinfartuale. Studio Clinico Multicentrico Comparativo vs CDP-Colina. Giorn It Ric. Clin. Ter. 1991; 12: 159–166
   Google Scholar
• Muratorio A., Bonuccelli U., Nuti A., Battistini N., Passero S. A Neutropic Approach to the Treatment of Multi-Infarct Dementia Using L-Alpha-Glycerylphosphorylcholine. Curr. Ther. Res. 1992; 52: 741–751
   Web of Science ®Google Scholar
• Paciaroni E., Tomassini P. F. Studio Clinico di Efficacia e Tollerabilità di αGFC (Colina Alfoscerato), Controllato vs Oxiracetam in Pazienti Affetti da Declino Cognitivo di Grado Lieve-Moderato su Base Vascolare. Giorn It Ric Ter. 1993; 14: 29–34
   Google Scholar
• Venn R. D. The Sandoz Clinical Assessment Geriatric (ScaG) Scale—a General Purpose Psychogeriatric Rating Scale. Gerontology 1983; 29: 185–198
   PubMed Web of Science ®Google Scholar
• Ban T. A., Panzarasa R. M., Borra S., Del Duchetto D., Fjetland O. K. Choline Alphoscerate in Elderly Patients with Cognitive Decline Due to Dementing Illness. New Trends Clin. Neuropharmacol. 1991; 5: 1–35
   Google Scholar
• Palleschi M., Zuccaro S. M. Valutazione di Efficacia e Tollerabilità di αGFC (Colina Alfoscerato) in Pazienti Affetti da Declino Cognitivo di Grado Lieve-Moderato. Geriatria 1992; 4: 61–65
   Google Scholar